Sinusitis Exclusion From Nasal Decongestant Labels Is Unsupported – Pfizer
This article was originally published in The Tan Sheet
Executive Summary
Physician intervention could be the only recourse for consumers suffering from sinusitis if FDA were to remove the indication from OTC product labels, according to Pfizer Consumer Healthcare
You may also be interested in...
Sinusitis Indication Removed From OTC Decongestant Monograph
Marketers of OTC nasal decongestants have an April 11, 2007 deadline to remove references to the indication "sinusitis" from product labeling in order to comply with a monograph amendment
Supplement GMPs Planned For September In “Unified Agenda”
FDA has slated September as the release date for the long-awaited dietary supplement current good manufacturing practices final rule, according to HHS' semi-annual "unified agenda" published May 16 in the Federal Register
FDA Proposes “Sinusitis” Exclusion From OTC Nasal Decongestant Monograph
FDA is seeking to amend the OTC nasal decongestant monograph by removing the indications that reference "sinusitis," the agency announced in a proposed rule slated for publication in the Aug. 2 Federal Register